USCOM (ASX:UCM) Total Receivables : A$0.53 Mil (As of Dec. 2023)

View and export this data going back to 2003. Start your Free Trial

What is USCOM Total Receivables?

USCOM's Total Receivables for the quarter that ended in Dec. 2023 was A$0.53 Mil.

USCOM Total Receivables Historical Data

The historical data trend for USCOM's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

USCOM Total Receivables Chart

USCOM Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Total Receivables

Get a 7-Day Free Trial

0.58

0.27

0.40

0.34

0.37

USCOM Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Receivables	Get a 7-Day Free Trial															0.30	0.34	0.45	0.37	0.53

USCOM Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

USCOM Total Receivables Related Terms

Thank you for viewing the detailed overview of USCOM's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

USCOM (ASX:UCM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » USCOM Ltd (ASX:UCM) » Definitions » Total Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

Level 8, 66 Clarence Street, Suite 2, Sydney, NSW, AUS, 2000

Website

https://www.uscom.com.au

USCOM Ltd is engaged in the development, design, manufacture, and marketing of premium non-invasive cardiovascular and pulmonary medical devices. The company's geographical segment includes Australia, Asia, America, Europe, and Other regions. It generates maximum revenue from Australia. The company offers USCOM 1A, a non-invasive hemodynamic monitor that measures cardiovascular function; BP+, a supra-systolic oscillometric central blood pressure monitor that measures blood pressure and blood pressure waveforms at the heart, SPIROSONIC, a pulmonary function testing device based on multi-path ultrasound technology and the VENTITEST and VENTITEST-S ultrasonic ventilator calibration devices for optimizing respiratory device performance.

USCOM (ASX:UCM) Headlines

No Headlines